



RECEIVED  
FEB 10 2003 2/3/03  
TECH CENTER  
PATENT  
Customer 100 22 852  
Attorney Docket No. 06478.1400-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
C. Jane ROBINSON et al. ) Group Art Unit: 1646  
Application No.: 10/046,278 ) Examiner: Unknown  
Filed: January 16, 2002 )  
For: Antithrombin III for Disorders )  
Caused by Angiogenesis )

Commissioner for Patents and Trademarks  
Washington, DC 20231

Sir:

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Office the documents listed on the attached PTO form 1449. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed documents, including any copending patent applications, are attached. Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

In lieu of a statement of relevance or translation of the non-English documents, an English language abstract of each document is enclosed.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

documents are material or constitute "prior art." If the Office applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: February 6, 2003

By:   
Elizabeth A. Doherty  
Reg. No. 50,894

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

# INFORMATION DISCLOSURE CITATION

OMB No. 0651-0011

RECEIVED

U.S. PATENT & TRADEMARK OFFICE  
FEB 13 2003  
TECH CENTER 1600/2900

Atty. Docket No.	06478.1463-00	Application No.	10/046,278
Applicant	C. Jane ROBINSON et al.		
Filing Date	January 16, 2002	Group:	1646

## U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate

## FOREIGN PATENT DOCUMENTS

	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
1	WO 00/20026 A2	4/13/2000	PCT	A 61 K	38/55	
2	WO 00/54801 A1	9/21/2000	PCT	A 61 K	38/48	
3	EP 1 075 840 A2	2/14/2001	EPO	A 61 K	38/57	Abstract
4	WO 02/22150 A2	3/21/2002	PCT	A 61 K	38/00	Abstract
5	EP 0 438 234 A1	7/24/1991	EPO	A 61 K	37/02	

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

6	B. Eisele and M. Lamy, "Clinical Experience with Antithrombin III Concentrates in Critically Ill Patients with Sepsis and Multiple Organ Failure," <i>Seminars in Thrombosis and Hemostasis</i> , 24(1):71-80 (1998).
7	R. Clemens, et al., "Antithrombin III Substitution Affects Survival Rate in a Murine Malaria Model," <i>Parasitology Research</i> , 76(1):36-38 (1989).
8	M.S. O'Reilly, et al., "Antiangiogenic Activity of the Cleaved Conformation of the Serpin Antithrombin," <i>Science</i> , 285(17):1926-1928 (1999).

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce